Nitric oxide inhibition sustains vasopressin-induced vasoconstriction

British Journal of Cancer

Volumn 71, Issue 5, 1995, Pages 942-944

  Dworkin, M J ^a   Carnochan, P ^b   Allen Mersh, T G ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Colorectal liver metastases; Nitric oxide; Vasopressin

Indexed keywords

ARGININE METHYL ESTER; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; VASOPRESSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG UPTAKE; INTRAARTERIAL DRUG ADMINISTRATION; LASER DOPPLER FLOWMETRY; LIVER BLOOD FLOW; LIVER PARENCHYMA; LIVER TUMOR; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR BLOOD FLOW; VASOCONSTRICTION;

ANIMAL; ARGININE; HEPATIC ARTERY; INFUSIONS, INTRA-ARTERIAL; LIVER; LIVER CIRCULATION; LIVER NEOPLASMS, EXPERIMENTAL; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; PERFUSION; RATS; RATS, INBRED STRAINS; SUPPORT, NON-U.S. GOV'T; VASOCONSTRICTION; VASOPRESSINS;

EID: 0029073854     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1995.182     Document Type: Article

References (15)

1. ACKERMAN NB, JACOBS R, BLOOM ND, AND POON TT. (1988). Increased capillary flow in intrahepatic tumours due to a-adrenergic effects of catecholamines. Cancer, 61, 1550–1554.
2. ALLEN-MERSH TG, EARLAM S, FORDY C, ABRAMS K, AND HOUGHTON J. (1994). Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet, 344, 1255–1260.
3. BURTON MA, GRAY BN, SELF GW, HEGGIE JC, AND TOWNSEND PS. (1985). Manipulation of experimental rat and liver tumour blood flow with angiotensin II. Cancer Res., 45, 5390–5393.
4. CONN HO, RAMSBY GR, AND STORER EH. (1973). Hepatic arterial escape from vasopressin-induced vasoconstriction: an angiographic investigation. Am. J. Roentgenol., 119, 102–108.
5. DWORKIN MJ, AND ALLEN-MERSH TG. (1991). Regional infusion chemotherapy for colorectal hepatic metastases -where is it going? Cancer Treat. Rev., 18, 213–224.
6. DWORKIN MJ, CARNOCHAN P, AND ALLEN-MERSH TG. (1992). Vasoactive agents do not increase blood flow to liver but endothelin does produce a rise in tumour to liver blood flow ratio (abstract). Br. J. Surg., 79, 1240.
7. DWORKIN MJ, ZWEIT J, DEEHAN B, CARNOCHAN P, ALLEN-MERSH TG. (1993). Is tumour blood flow related to cytotoxic drug uptake (abstract). Br. J. Surg., 80, 1459.
8. GOLDBERG JA, MURRAY T, KERR DJ, WILLMOTT N, BESSENT RG, McKILLOP JH, AND McARDLE CS. (1991). The use of angiotensin II as a potential method of targeting cytotoxic microspheres in patients with intrahepatic tumour. Br. J. Cancer, 63, 308 -310.
9. HEMMINGWAY DM. CHANG D, COOKE TG, AND JENKINS SA. (1991). The effects of vasopressin infusion on hepatic haemo-dynamics in an experimental model of liver metastases. Br. J. Cancer, 64, 212–214.
10. KAWADA N, TRAN-THI T, KLEIN H, AND DECKER K. (1993). The contraction of hepatic stellate cells stimulated with vasoactive substances. Eur. J. Biochem., 213, 815–823.
11. KRYLOVA NV. (1969). Characteristics of microcirculation in experimental tumours. Bibl. Anat., 10, 301–303.
12. MATHIE RT, RALEVIC V, ALEXANDER B, AND BURNSTOCK G. (1991). Nitric oxide is the mediator of ATP-induced dilation of the rabbit hepatic arterial bed. Br. J. Pharmacol., 103, 1602–1606.
13. MONCADA S, PALMER RMJ, AND HIGGS EA. (1991). Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol. Rev., 43, 109–142.
14. ROUGHER P, LAPLANCHE A. HUGUIER M, HAY JM, OLLIVIER JM, ESCAT J, SALMON R, JULIEN M, ROULLET AUDY JC, GALLOT D, GOUZI JL, PAILLER JM, EUSA D, LACAINE F, ROOS S, ROTMAN N, LUBOINSKI M, AND LASSER P. (1992). Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long term results of a prospective randomized trial. J. Clin. Oncol., 10, 1112–1118.
15. SASAKI Y, IMAOKA S, HASEGAWA Y, NAKANO S, ISHIKAWA O, OHIGASHI H, TENIGUCHI K. KOYAMA H, IWANAGA T, AND TERASAWA T. (1985). Changes in distribution of hepatic blood flow induced by intra-arterial infusions of angiotensin II in human hepatic cancer. Cancer, 55, 311–316.